Products of the X and Polymerase Genes of Hepadnaviruses - Mark Feitelson

Abstract

Funding Agency

Agency: National Institute of Health (NIH)
Institute: National Cancer Institute (NCI)
Type: First Independent Research Support & Transition (FIRST) Awards (R29)
Project #: 5R29CA048656-04
Application #: 3459170
Study Section: Virology Study Section (VR)

Project Start: 1988-03-01
Project End: 1991-05-31
Budget Start: 1991-03-01
Budget End: 1991-05-31
Support Year: 4
Fiscal Year: 1991
Total Cost
Indirect Cost

Institution

Name: Fox Chase Cancer Center
Department
Type
DUNS #: 042250712

City: Philadelphia
State: PA
Country: United States
Zip Code: 19111

Related projects


NIH 1992 R29 CA	Products of the X and Polymerase Genes of Hepadnaviruses Feitelson, Mark A. / Thomas Jefferson University
NIH 1991 R29 CA	Products of the X and Polymerase Genes of Hepadnaviruses Feitelson, Mark A. / Fox Chase Cancer Center
NIH 1991 R29 CA	Products of the X and Polymerase Genes of Hepadnaviruses Feitelson, Mark A. / Thomas Jefferson University
NIH 1990 R29 CA	Products of the X and Polymerase Genes of Hepadnaviruses Feitelson, Mark A. / Fox Chase Cancer Center
NIH 1989 R29 CA	Products of the X and Polymerase Genes of Hepadnaviruses Feitelson, Mark A. / Fox Chase Cancer Center
NIH 1988 R29 CA	Products of the X and Polymerase Genes of Hepadnaviruses Feitelson, Mark A. / Fox Chase Cancer Center

Publications

Schinazi, Raymond F; Bassit, Leda; Clayton, Marcia M et al. (2012) Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrob Agents Chemother 56:6186-91

Comments

Be the first to comment on Mark Feitelson's grant